RBC Capital lowered the firm’s price target on GoHealth to $13 from $20 and keeps a Sector Perform rating on the shares. The company’s Q4 results came in well below expectations driven by lower submissions, and its volumes were impacted by fewer plan switchers as a result of limited Medicare Advantage product differentiation, the analyst tells investors in a research note. GoHealth’s cash flow from operations is also expected to be flat to slightly up as the company continues to transition to its Encompass model, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GOCO:
- GoHealth sees 2024 revenue flat, operating cash flow flat to slightly up
- GoHealth Reports Fourth Quarter and Fiscal 2023 Results
- GoHealth reports Q4 EPS (22c) vs. ($7.00) last year
- GOCO Earnings this Week: How Will it Perform?
- GoHealth to Announce Fourth Quarter and Year End 2023 Results on March 14, 2024